Manufacturers report data from interim analysis of ODYSSEY Study for tradipitant in COVID-19 pneumonia

Interim analysis of first 60 patients in study showed that this neurokinin 1 antagonist accelerated clinical improvement by day 7 vs placebo (HR=2.55, p=0.0375). Similar overall rates of improvement and mortality were observed for the two treatment arms at day 28 however.


Biospace Inc.